person · Reporting owner

VERNON W ANTHONY

Disclosed activity across 7 companies

Tapewire entity: 40917
SEC CIK: 0001369091

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Intersect ENT, Inc.XENT · Entity 127294	Director	June 04, 2020	June 08, 2020
MCCORMICK & CO INCMKC · Entity 1416	Director	February 15, 2026	February 18, 2026
NovoCure LtdNVCR · Entity 4494	Director	June 03, 2026	June 05, 2026
Nuvation Bio Inc.NUVB · Entity 4384	Director	May 21, 2026	May 27, 2026
Sio Gene Therapies Inc.AXON · Entity 130622	Director	May 15, 2017	May 16, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Intersect ENT, Inc.

Report date June 04, 2020 · Filed June 08, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,383	Reported balance After 2020-06-04 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2020-06-04 · Grant · Acquired 5,011 · Balance 11,383 F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2: Includes 5,011 restricted stock units.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03	Direct	9,666	Reported balance After 2020-06-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-06-04 · Grant · Acquired 9,666 · Balance 9,666 F3: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021.

F2: Includes 5,011 restricted stock units.

F3: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020.

MCCORMICK & CO INC

Report date February 15, 2026 · Filed February 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock - VotingSEC Table I · non-derivative	Direct	14,048	Reported balance After 2026-02-15 transaction · row 1 1 source row Row 1 · 2026-02-15 · Exercise / conversion · Acquired 2,222 · Balance 14,048 F1: Restricted Stock Units; No purchase price required.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-02-15 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-15 · Exercise / conversion · Disposed 2,222 · Balance 0 F1: Restricted Stock Units; No purchase price required. F3: The Restricted Stock Units granted on February 7, 2025. F2: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Units; No purchase price required.

F2: The reported Restricted Stock Units entitles the Reporting Person to receive an annual distribution of common stock equal to 100% of the grant.

F3: The Restricted Stock Units granted on February 7, 2025.

NovoCure Ltd

Report date June 03, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	209,267	Reported balance After 2026-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 209,267 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03	Direct	16,999	Reported balance After 2026-06-03 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.

Nuvation Bio Inc.

Report date May 21, 2026 · Filed May 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.79 · Expires 2036-05-20	Direct	123,397	Reported balance After 2026-05-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-21 · Grant · Acquired 123,397 · Balance 123,397 F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the shares subject to the option shall vest on the earlier of: (i) the one-year anniversary of the grant date (May 21, 2026); or (ii) the next shareholder annual meeting, subject to the Reporting Person's continuous service through such applicable vesting date.

Sio Gene Therapies Inc.

Report date May 15, 2017 · Filed May 16, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.90 · Expires 2027-05-14	Direct	70,000	Reported balance After 2017-05-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-05-15 · Grant · Acquired 70,000 · Balance 70,000 F1: This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MEDIVATION, INC.

Report date September 28, 2016 · Filed September 30, 2016

Section 16 reporting ended · disclosed 2016-09-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2016-09-28 transaction · row 1 1 source row Row 1 · 2016-09-28 · Other · Disposed 17,742 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal. F2: Includes 2,972 unvested shares subject to a restricted stock award.
Common StockSEC Table I · non-derivative	IndirectSpouse's Trust	Reported balance After 2016-09-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2016-09-28 · Other · Disposed 15,000 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.60 · Expires 2019-06-30	Direct	Reported balance After 2016-09-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.21 · Expires 2020-06-30	Direct	Reported balance After 2016-09-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2021-07-15	Direct	Reported balance After 2016-09-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2016-09-28 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.74 · Expires 2022-07-16	Direct	Reported balance After 2016-09-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2016-09-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.60 · Expires 2023-06-28	Direct	Reported balance After 2016-09-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2016-09-28 · Disposition to issuer · Disposed 12,232 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.89 · Expires 2024-06-27	Direct	Reported balance After 2016-09-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2016-09-28 · Disposition to issuer · Disposed 9,584 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.45 · Expires 2025-06-16	Direct	Reported balance After 2016-09-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2016-09-28 · Disposition to issuer · Disposed 6,284 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.89 · Expires 2026-06-22	Direct	Reported balance After 2016-09-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2016-09-28 · Disposition to issuer · Disposed 6,228 · Balance 0 F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated August 20, 2016, among the Issuer, Pfizer Inc., a Delaware corporation ("Parent"), and Montreal, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), in exchange for a cash consideration of $81.50 per share (without interest) subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). In connection with the Merger, Purchaser offered to purchase all of the outstanding shares of common stock, par value $0.01 per share of the Issuer, at a price of $81.50 per share, net to the seller in cash (without interest) but subject to any required withholding of taxes, upon the terms and conditions set forth in the offer to purchase dated August 30, 2016, and in the related letter of transmittal.

F2: Includes 2,972 unvested shares subject to a restricted stock award.

F3: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.

WHITEWAVE FOODS Co

Report date April 12, 2017 · Filed April 13, 2017

Section 16 reporting ended · disclosed 2017-04-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
common stockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-12 transaction · row 1 1 source row Row 1 · 2017-04-12 · Disposition to issuer · Disposed 6,300 · Balance 0 F1: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.91 · Expires 2026-01-01	Direct	Reported balance After 2017-04-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-12 · Disposition to issuer · Disposed 1,226 · Balance 0 F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.
stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.09 · Expires 2026-02-15	Direct	Reported balance After 2017-04-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-12 · Disposition to issuer · Disposed 5,376 · Balance 0 F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.

Filing footnotes · ownership attribution and instrument terms

F1: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash.

F2: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
April 01, 2020 Filed Apr 3, 2020 18:07 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	2,262	$0.00 Strike: $138.62	$0.00	Disclosure SEC source: 0000063754-20-000078 · edgar.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,262 Underlying: Common Stock - Voting · 2,262 shares Expires not disclosed F3 · derivative.exercise_date: The Options vest in full on 3/15/2021. F3 · derivative.expiration_date: The Options vest in full on 3/15/2021. Read SEC document
April 01, 2020 Filed Apr 3, 2020 18:07 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	734	$0.00	$0.00	Disclosure SEC source: 0000063754-20-000078 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock - Voting · 734 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in full on 3/15/2021 and are settled in an equial number of shares of Common Stock. F2 · derivative.expiration_date: The Restricted Stock Units vest in full on 3/15/2021 and are settled in an equial number of shares of Common Stock. Read SEC document
March 15, 2020 Filed Mar 17, 2020 20:11 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	689	$0.00	$0.00	Disclosure SEC source: 0000063754-20-000049 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F2 · price: Restricted Stock Units granted on March 27, 2019. F3 · derivative.exercise_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. F3 · derivative.expiration_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2020 Filed Mar 17, 2020 20:11 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	689	Not disclosed	Not disclosed	Disclosure SEC source: 0000063754-20-000049 · edgar.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; no purchase price required. Read SEC document
February 10, 2020 Filed Feb 12, 2021 22:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	50,000	$10.00	$500,000.00	Disclosure SEC source: 0001209191-21-010362 · doc4.xml · nonDerivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,100 F2 · shares: On October 20, 2020, the Issuer entered into subscription agreements (the "Subscription Agreements") with certain investors (the "PIPE Investors") pursuant to which such investors agreed to purchase, immediately prior to the closing of the Business Combination, as defined herein, an aggregate of $476,550,000 of the Issuer's shares of Class A Common Stock at a price of $10.00 per share, or an aggregate of 47,655,000 shares of Class A Common Stock. The Reporting Person is among the PIPE Investors. Read SEC document
February 10, 2020 Filed Feb 12, 2021 22:56 UTC	Nuvation Bio Inc. NUVB · Entity 4384	GrantClass A Common Stock	254,100	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-21-010362 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,100 F1 · price: Received pursuant to the Agreement and Plan of Merger, dated as of October 20, 2020, by and among Panacea Acquisition Corp. ("Panacea") and Panacea Merger Subsidiary Corp., a direct, wholly-owned subsidiary of Panacea ("Merger Sub"), and Nuvation Bio Inc. ("Legacy Nuvation") pursuant to which, as a result of a merger between Legacy Nuvation and Merger Sub, Legacy Nuvation became a direct, wholly-owned subsidiary of Panacea, which subsequently changed its name to Nuvation Bio Inc. (the "Issuer"). Read SEC document
August 29, 2019 Filed Sep 3, 2019 20:20 UTC	NovoCure Ltd NVCR · Entity 4494	SaleOrdinary Shares	100,000	$91.03	$9,103,100.00	Disclosure SEC source: 0001209191-19-047956 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,589 F1 · price: On August 29, 2019, Mr. Vernon sold 100,000 shares in multiple trades at prices ranging from $91.00 to $91.14. The price reported above reflects the weighted average sale price. Mr. Vernon hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:11 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	5,172	$0.00 Strike: $23.02	$0.00	Disclosure SEC source: 0001562180-19-003400 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Common Stock · 5,172 shares Expires 2029-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2019. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:11 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	2,312	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003400 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,372 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2020. F2 · balance_after: Includes 2,312 restricted stock units. Read SEC document
May 22, 2019 Filed May 24, 2019 20:17 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	6,340	$0.00 Strike: $51.36	$0.00	Disclosure SEC source: 0001209191-19-032698 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,340 Underlying: Ordinary Shares · 6,340 shares Expires 2029-05-22 F2 · derivative.exercise_date: Options to buy 6,340 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document
May 22, 2019 Filed May 24, 2019 20:17 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Units	3,359	$0.00	$0.00	Disclosure SEC source: 0001209191-19-032698 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 258,589 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2020 annual general meeting of shareholders. Read SEC document
May 21, 2019 Filed May 22, 2019 20:25 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionRestricted Stock Units · Derivative	6,145	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-19-032055 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document
May 21, 2019 Filed May 22, 2019 20:25 UTC	NovoCure Ltd NVCR · Entity 4494	Exercise / conversionOrdinary Shares	6,145	$48.87	$300,306.15	Disclosure SEC source: 0001209191-19-032055 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,230 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 27, 2019 Filed Mar 29, 2019 15:15 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	2,182	$0.00 Strike: $147.39	$0.00	Disclosure SEC source: 0000063754-19-000067 · edgar.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,182 Underlying: Common Stock - Voting · 2,182 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on 3/15/2020. F3 · derivative.expiration_date: The options vest in full on 3/15/2020. Read SEC document
March 27, 2019 Filed Mar 29, 2019 15:15 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	689	$0.00	$0.00	Disclosure SEC source: 0000063754-19-000067 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 689 Underlying: Common Stock - Voting · 689 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in full on 3/15/2020 and are settled in an equal number of shares of Common Stock. F2 · derivative.expiration_date: The restricted stock units vest in full on 3/15/2020 and are settled in an equal number of shares of Common Stock. Read SEC document
March 15, 2019 Filed Mar 19, 2019 19:12 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	962	$0.00	$0.00	Disclosure SEC source: 0000063754-19-000042 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 962 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F3 · price: Restricted Stock Units granted on March 28, 2018. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2019 Filed Mar 19, 2019 19:12 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	962	Not disclosed	Not disclosed	Disclosure SEC source: 0000063754-19-000042 · edgar.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; no purchase price required. Read SEC document
January 16, 2019 Filed Jan 18, 2019 17:37 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	3,220	$0.00 Strike: $28.58	$0.00	Disclosure SEC source: 0001562180-19-000370 · primarydocument.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,220 Underlying: Common Stock · 3,220 shares Expires 2029-01-15 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2019. Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:19 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	3,473	$0.00 Strike: $42.05	$0.00	Disclosure SEC source: 0001562180-18-002916 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018. Read SEC document
June 05, 2018 Filed Jun 7, 2018 17:19 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	1,514	$0.00	$0.00	Disclosure SEC source: 0001562180-18-002916 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,060 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019. F2 · balance_after: Includes 1,514 RSUs. Read SEC document
May 31, 2018 Filed Jun 5, 2018 00:09 UTC	NovoCure Ltd NVCR · Entity 4494	GrantRestricted Stock Unit · Derivative	6,145	$0.00	$0.00	Disclosure SEC source: 0001209191-18-035381 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,145 Underlying: Ordinary Shares · 6,145 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. F3 · derivative.expiration_date: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document
May 31, 2018 Filed Jun 5, 2018 00:09 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	12,345	$0.00 Strike: $31.45	$0.00	Disclosure SEC source: 0001209191-18-035381 · doc4.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,345 Underlying: Ordinary Shares · 12,345 shares Expires 2028-05-31 F1 · derivative.exercise_date: Options to buy 12,345 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders. Read SEC document
March 28, 2018 Filed Mar 30, 2018 13:52 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	2,956	$0.00 Strike: $105.95	$0.00	Disclosure SEC source: 0001314598-18-000067 · edgar.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,956 Underlying: Common Stock - Voting · 2,956 shares Expires not disclosed F3 · derivative.exercise_date: The options vest in full on 3/15/2019. F3 · derivative.expiration_date: The options vest in full on 3/15/2019. Read SEC document
March 28, 2018 Filed Mar 30, 2018 13:52 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	962	$0.00	$0.00	Disclosure SEC source: 0001314598-18-000067 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962 Underlying: Common Stock - Voting · 962 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in full on 3/15/2019 and are settled in an equal number of shares of Common Stock. F2 · derivative.expiration_date: The restricted stock units vest in full on 3/15/2019 and are settled in an equal number of shares of Common Stock. Read SEC document
March 15, 2018 Filed Mar 19, 2018 17:39 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionRestricted Stock Units · Derivative	990	$0.00	$0.00	Disclosure SEC source: 0001314598-18-000040 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock - Voting · 990 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units; no purchase price required. F3 · price: Restricted Stock Units granted on May 23, 2017. F2 · derivative.exercise_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. F2 · derivative.expiration_date: The reported Restricted Stock Units entitles the reporting person to receive an annual distribution of common stock equal to 100% of the grant. Read SEC document
March 15, 2018 Filed Mar 19, 2018 17:39 UTC	MCCORMICK & CO INC MKC · Entity 1416	Exercise / conversionCommon Stock - Voting	990	Not disclosed	Not disclosed	Disclosure SEC source: 0001314598-18-000040 · edgar.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units; no purchase price required. Read SEC document
June 01, 2017 Filed Jun 5, 2017 19:29 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	6,035	$0.00 Strike: $26.05	$0.00	Disclosure SEC source: 0001562180-17-002201 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Underlying: Common Stock · 6,035 shares Expires 2027-05-31 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document
June 01, 2017 Filed Jun 5, 2017 19:29 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	2,546	$0.00	$0.00	Disclosure SEC source: 0001562180-17-002201 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018. Read SEC document
May 23, 2017 Filed May 25, 2017 15:14 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantOptions - Right to Buy · Derivative	3,260	$0.00 Strike: $102.53	$0.00	Disclosure SEC source: 0001314598-17-000054 · edgar.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,260 Underlying: Common Stock - Voting · 3,260 shares Expires not disclosed F3 · derivative.exercise_date: The option vests in full on 3/15/2018. F3 · derivative.expiration_date: The option vests in full on 3/15/2018. Read SEC document
May 23, 2017 Filed May 25, 2017 15:14 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantRestricted Stock Units · Derivative	990	$0.00	$0.00	Disclosure SEC source: 0001314598-17-000054 · edgar.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 990 Underlying: Common Stock - Voting · 990 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on 3/15/2018, and are settled in an equal number of shares of Common Stock. F2 · derivative.expiration_date: The restricted stock units vest in full on 3/15/2018, and are settled in an equal number of shares of Common Stock. Read SEC document
May 23, 2017 Filed May 25, 2017 15:14 UTC	MCCORMICK & CO INC MKC · Entity 1416	GrantCommon Stock - Voting	147	$102.53	$15,071.91	Disclosure SEC source: 0001314598-17-000054 · edgar.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147 Read SEC document
May 15, 2017 Filed May 16, 2017 21:09 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	GrantStock Option (Right to Buy) · Derivative	70,000	$0.00 Strike: $21.90	$0.00	Disclosure SEC source: 0001636050-17-000021 · wf-form4_149496896034311.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Shares · 70,000 shares Expires 2027-05-14 F1 · derivative.exercise_date: This option vests over a period of three years, with one third of the common shares underlying the option vesting on each of the first, second and third anniversaries of April 7, 2017, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document
May 10, 2017 Filed May 12, 2017 20:56 UTC	NovoCure Ltd NVCR · Entity 4494	GrantOptions to Buy Ordinary Shares · Derivative	23,600	$0.00 Strike: $12.30	$0.00	Disclosure SEC source: 0001209191-17-032038 · doc4.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,600 Underlying: Ordinary Shares · 23,600 shares Expires 2027-05-10 F1 · derivative.exercise_date: Options to buy 23,600 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the date of the Company's 2018 annual general meeting of shareholders. Read SEC document
April 17, 2017 Filed Apr 19, 2017 20:08 UTC	Sio Gene Therapies Inc. AXON · Entity 130622	PurchaseCommon Shares	53,937	$18.54	$999,991.98	Disclosure SEC source: 0001209191-17-027440 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,937 Read SEC document
April 12, 2017 Filed Apr 13, 2017 20:33 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Disposition to issuerstock option (right to buy) · Derivative	5,376	Not disclosed Strike: $36.09	Not disclosed	Disclosure SEC source: 0001209191-17-026871 · doc4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 5,376 shares Expires 2026-02-15 F2 · shares: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option. F2 · price: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option. Read SEC document
April 12, 2017 Filed Apr 13, 2017 20:33 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Disposition to issuerstock option (right to buy) · Derivative	1,226	Not disclosed Strike: $38.91	Not disclosed	Disclosure SEC source: 0001209191-17-026871 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 1,226 shares Expires 2026-01-01 F2 · shares: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option. F2 · price: At the effective time of the merger, each stock option was cancelled in exchange for a per share cash payment equal to the difference between the $56.25 merger consideration per share and the exercise price of the stock option. Read SEC document
April 12, 2017 Filed Apr 13, 2017 20:33 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Disposition to issuercommon stock	6,300	$56.25	$354,375.00	Disclosure SEC source: 0001209191-17-026871 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash. F1 · price: At the effective time of the merger with Danone S.A., each outstanding share of WhiteWave common stock automatically was converted into the right to receive the $56.25 merger consideration per share in cash. Read SEC document
February 15, 2017 Filed Feb 16, 2017 23:21 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Exercise / conversionrestricted stock unit · Derivative	1,663	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-011676 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 1,663 shares Expires 2017-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 15, 2017 Filed Feb 16, 2017 23:21 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Exercise / conversioncommon stock	1,663	$0.00	$0.00	Disclosure SEC source: 0001209191-17-011676 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The reporting person received shares of WhiteWave common stock upon the vesting of a restricted stock unit. Read SEC document
January 18, 2017 Filed Jan 20, 2017 19:36 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Options (Right to buy) · Derivative	7,570	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001562180-17-000297 · primarydocument.xml · derivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Underlying: Common Stock · 7,570 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2017. Read SEC document
January 01, 2017 Filed Jan 23, 2017 22:53 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Exercise / conversionRestricted Stock Unit · Derivative	481	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001209191-17-005160 · doc4.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common stock · 481 shares Expires 2017-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 01, 2017 Filed Jan 23, 2017 22:53 UTC	WHITEWAVE FOODS Co WWAV · Entity 176959	Exercise / conversioncommon stock	481	$0.00	$0.00	Disclosure SEC source: 0001209191-17-005160 · doc4.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,637 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	6,228	Not disclosed Strike: $58.89	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 10 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,228 shares Expires 2026-06-22 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	6,284	Not disclosed Strike: $55.45	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 9 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,284 shares Expires 2025-06-16 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	9,584	Not disclosed Strike: $38.89	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 8 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,584 shares Expires 2024-06-27 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	12,232	Not disclosed Strike: $24.60	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 7 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,232 shares Expires 2023-06-28 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	30,000	Not disclosed Strike: $23.74	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 6 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2022-07-16 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	60,000	Not disclosed Strike: $5.50	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 5 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2021-07-15 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	60,000	Not disclosed Strike: $2.21	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 4 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2020-06-30 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document
September 28, 2016 Filed Sep 30, 2016 17:59 UTC	MEDIVATION, INC. MDVN · Entity 181987	Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative	60,000	Not disclosed Strike: $5.60	Not disclosed	Disclosure SEC source: 0001209191-16-143396 · doc4.xml · derivative · entry 3 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2019-06-30 F3 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F3 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $81.50 per share (without interest) subject to any required withholding of taxes minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.